Alpha Tau reports 100% response rate in six evaluable patients in recurrent glioblastoma trial
DRTS•Alpha Tau Medical reported that all six evaluable patients in its U.S. REGAIN trial for recurrent glioblastoma showed tumor responses, mostly complete responses. All eight treated patients were alive as of November 11, 2026.
1. Interim trial results
Alpha Tau Medical announced interim results from its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma. Treatment was delivered as planned in all eight patients, with no unanticipated serious adverse events, and no definitive local recurrence was observed. Some imaging findings remain unresolved between radiation-related tissue damage and tumor progression. The results were presented at the Society for Neuro-Oncology annual meeting in Philadelphia, held November 12-15, 2026.




